TheraVet - H1 23 business update

TheraVet published a business update. The company comes back on the progress made during H1 23. One of the main events was the commercial launch of BIOCERA-VET combined with antibiotics. Moreover, the update highlights that no further delays are currently foreseen in the EU study evaluating VISCO-VET. Given the 12-15 months delay announced, we expect enrollment to be completed soon with interim results to be published by the end of the year. TheraVet is expanding its offering with the developmen...